Correlation Between Monopar Therapeutics and Scopus Biopharma

Can any of the company-specific risk be diversified away by investing in both Monopar Therapeutics and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monopar Therapeutics and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Monopar Therapeutics and Scopus Biopharma, you can compare the effects of market volatilities on Monopar Therapeutics and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monopar Therapeutics with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monopar Therapeutics and Scopus Biopharma.

Diversification Opportunities for Monopar Therapeutics and Scopus Biopharma

-0.37

Correlation Coefficient

Monopar Therapeutics  Scopus Biopharma

Very good diversification

The 3 months correlation between Monopar and Scopus is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Monopar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monopar Therapeutics are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Monopar Therapeutics i.e., Monopar Therapeutics and Scopus Biopharma go up and down completely randomly.

Pair Corralation between Monopar Therapeutics and Scopus Biopharma

Given the investment horizon of 90 days Monopar Therapeutics is expected to generate 1.29 times more return on investment than Scopus Biopharma. However, Monopar Therapeutics is 1.29 times more volatile than Scopus Biopharma. It trades about 0.05 of its potential returns per unit of risk. Scopus Biopharma is currently generating about 0.01 per unit of risk. If you would invest  1,110  in Monopar Therapeutics on September 3, 2024 and sell it today you would earn a total of  1,143  from holding Monopar Therapeutics or generate 102.97% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	7.88%
Values	Daily Returns

Monopar Therapeutics  vs.  Scopus Biopharma

Monopar Therapeutics

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Monopar Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Monopar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Scopus Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Monopar Therapeutics and Scopus Biopharma

The main advantage of trading using opposite Monopar Therapeutics and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monopar Therapeutics position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.

The idea behind Monopar Therapeutics and Scopus Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.